West African journal of medicine · 2005
Efficacy of nebulized furosemide in children with moderate attack of asthma.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alshehri M, Almegamesi T, Alfrayh A
Аннотация
BACKGROUND: Bronchodilators are the most commonly used drugs for asthma. However, alternative treatment is necessary for those patients who experience adverse effects from bronchodilators.
OBJECTIVE: To investigate the efficacy of nebulized furosemide in children with moderate asthma exacerbations.
METHOD AND MATERIALS: A double-blind randomized, controlled trial involving three groups of children with moderate attack of asthma. Twenty children were enrolled in group A and received nebulized albuterol, 20 children in group B received nebulized furosemide and 19 children in group C received both albuterol and furosemide. Pulmonary function parameters, peak flow rates, respiratory rate, oxygen saturation and clinical scores were obtained before and after treatment.
RESULTS: The maximum increases in FEV1 achieved were 21.1 +/- 4.6 %, 20.8 +/- 3.2 and 21.7 +/- 4.9 in groups A, B and C respectively. The differences between the groups were not significant. Maximum increase in FVC was 20.3 +/- 1.6, 22.5 +/- 5.8 % and 24.5 +/- 4.9 % in groups B and C respectively. The difference between the three groups was not statistically significant. With regards to peak expiratory flow rate (PEFR), the mean increase after treatment was 23.5 +/- 8.6% and 21.8 +/- 6.3% in groups A and B respectively. There was significant increase in PEFR in group C children (26.0 +/- 9.1%; p = 0.01). There was no statistical significant difference among the three groups regarding the improvement in respiratory rate, SaO2 and clinical scores.
CONCLUSION: Combination of both furosemide and albuterol led to significant increase in peak flow rate but it did not significantly affect FEV1, FVC, FEF 25-75, respiratory rate, SaO2 or clinical scores as compared to other groups. There were no significant adverse effects from the three drugs used.
OBJECTIVE: To investigate the efficacy of nebulized furosemide in children with moderate asthma exacerbations.
METHOD AND MATERIALS: A double-blind randomized, controlled trial involving three groups of children with moderate attack of asthma. Twenty children were enrolled in group A and received nebulized albuterol, 20 children in group B received nebulized furosemide and 19 children in group C received both albuterol and furosemide. Pulmonary function parameters, peak flow rates, respiratory rate, oxygen saturation and clinical scores were obtained before and after treatment.
RESULTS: The maximum increases in FEV1 achieved were 21.1 +/- 4.6 %, 20.8 +/- 3.2 and 21.7 +/- 4.9 in groups A, B and C respectively. The differences between the groups were not significant. Maximum increase in FVC was 20.3 +/- 1.6, 22.5 +/- 5.8 % and 24.5 +/- 4.9 % in groups B and C respectively. The difference between the three groups was not statistically significant. With regards to peak expiratory flow rate (PEFR), the mean increase after treatment was 23.5 +/- 8.6% and 21.8 +/- 6.3% in groups A and B respectively. There was significant increase in PEFR in group C children (26.0 +/- 9.1%; p = 0.01). There was no statistical significant difference among the three groups regarding the improvement in respiratory rate, SaO2 and clinical scores.
CONCLUSION: Combination of both furosemide and albuterol led to significant increase in peak flow rate but it did not significantly affect FEV1, FVC, FEF 25-75, respiratory rate, SaO2 or clinical scores as compared to other groups. There were no significant adverse effects from the three drugs used.